Gary J. Doherty

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

L. Antonuzzo, G. Ostoros, Shugeng Gao, 2023, The New England journal of medicine.

Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.

J. Chaft, Tetsuya Mitsudomi, David Harpole, 2024, Journal of Clinical Oncology.